After the acquisition, KKR appointed Cipla veteran Nikhil Chopra in October 2020 as JBs chief executive.. He put the Mumbai-based drugmaker on an accelerated growth path, making four acquisitions and investing $200 million in the last four years along with a fresh go to-market strategy involving therapy diversification, raising the productivity of medical representatives, optimising costs, making big brands even larger, and chronic therapies.